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At the 2010 Osteoarthritis Research Society International (OARSI) congress in Brussels I was asked to
present on “Genetics” in the “Year in Review” session. This gave me an opportunity to reﬂect on the talk
that I gave on the same topic at the 2007 OARSI congress in Ft Lauderdale, Florida. My 2007 talk was very
upbeat and ended with the hostage to fortune statement “The next few years will provide tremendous
clarity in our genetic understanding of osteoarthritis”.
 2011 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
So why was I so upbeat in 2007? Several factors had come
together in that year that would have made even the coldest
skeptical heart warm a little. Firstly, there had been the recent
publication in Nature of the seminal paper from the Wellcome
Trust Case Control Consortium (WTCCC) that had demonstrated
the ability, across a number of common diseases, to map
compelling association signals by genome-wide association scan
(GWAS) technology. In the discovery part of the GWAS this
breakthrough study used the relatively small number of 2000
cases for each disease, a ﬁgure that could easily be surpassed by
osteoarthritis (OA) collections. Secondly, OA genetics had been
basking in the glow of a number of recent successes based on
candidate gene studies1. Despite the fact that most of the reported
signals didn’t replicate, optimism remained high as the failure was
easily (perhaps too easily?) put down to “heterogeneity” encom-
passing, for example, the wrong disease classiﬁcation, the wrong
joint or thewrong ethnic group being genotyped in the replication
studies. Finally, a number of investigators, many working in
collaborative projects, had managed to persuade funding bodies
to part with substantial sums to fund the hunt and consequent
characterization of OA susceptibility alleles. All was set fair for OA
in 2007 so why, in 2010, does that bold statement of mine ring
somewhat hollow?o: John Loughlin, Newcastle
loskeletal Research Group,
l School, Framlington Place,
s Research Society International. PLike most breakthroughs the initial euphoria subsides and
a more sober assessment begins. There is no doubt that GWAS has
proved a spectacular success at accruing large sums of grant
funding, at ﬁnding associated alleles (some of which occasionally
shed insight into potentially novel disease pathways) and at
generating lots of publications. What it hasn’t proved particularly
good at, for the vast majority of traits studied, is accounting for
a signiﬁcant proportion of the genetic risk of the trait under
investigation e the so-called “missing heritability” problem2. A
number of possible causes of this have been put forward. For
example, (1) most susceptibility alleles have very small individual
effects on the trait (low odds ratios [ORs]) and as such are beyond
detection unless tens or even hundreds of thousands of “cases” are
genotyped, (2) many susceptibility alleles are rare, with minor
allele frequencies (MAFs) less than 2.5%, and are not therefore
captured efﬁciently by the GWAS genotyping arrays that have
been employed so far; (3) some associations may be accounted for
by different types of polymorphism than the single nucleotide
polymorphism (SNPs) that make up the bulk of the variants on
most arrays. Solutions to these problems have been proposed with
a current vogue being whole-genome sequencing to identify all
rare variants, including those with MAFs as low as 0.1%. If, like the
common variants, the rare variants also have small ORs, then there
will be a need for cohorts several-fold greater in size than those
currently collected. This is a daunting possibility, particularly for
a dichotomous (yes/no) disease such as OA. If however the vari-
ants are responsible for more familial, early-onset forms of the
disease then larger effect sizes of the alleles are predicted, hope-
fully making their detection easier. So, with these and other
lessons learned perhaps its not too surprising that the yield so far
from OA GWAS studies is not as bountiful as hoped for.ublished by Elsevier Ltd. All rights reserved.
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there have been three OA GWAS studies reported: the Rotterdam,
Tokyo and the UK arcOGEN studies3e5.
The Rotterdam GWAS
This study involved a GWAS in a Dutch cohort followed by
replication of signals in additional European cohorts, including North
Americans of European descent. The discovery component of the
study wasmoderately powered, with 1,341 cases and 3,496 controls,
whilst the overall numbers for the discovery and replication
combined were respectable, with 14,938 cases and 39,000 controls.
A signal, with a meta-analysis P-value of 8 108 and an OR of 1.14,
was reported to a region of chromosome 7q22 harboring several
genes in a linkage disequilibrium (LD) block extending over 500 kb.
The signiﬁcance of this association has been extended in a separate
report that added some additional cohorts to the original meta-
analysis6. The 7q22 locus contains six known genes: PRKAR2B,
encoding protein kinase-cAMP-dependent-regulatory-type II-b;
HPB1, encoding HMG-box transcription factor 1; COG5, encoding
component of oligomeric golgi complex 5; GPR22, encoding
G protein-coupled receptor 22; DUS4L, encoding dihydrouridine
synthase 4-like and; BCAP29, encoding B-cell receptor-associated
protein 29. The expression of the six genes in joint tissues from
humans and mice was investigated revealing that all, except GPR22,
showed widespread expression. Intriguingly, further studies
revealed that GPR22 harbored an expression quantitative trait locus
(eQTL) tagged by a SNP in high LD with the association signal. This
eQTL was detected using an expression database for transformed
lymphoblast cell-lines. Whether this lymphoblast eQTL is likely to be
relevant to the pathology of OA or is simply a coincidence reﬂecting
the existence of cell-type speciﬁc eQTLs was not resolved. The Rot-
terdam paper reported the presence of GPR22 protein in the carti-
lage chondrocytes of mice that had an induced form of arthritis but
did not report whether GPR22 protein was also detected in human
arthritic cartilage. At the 2010 Osteoarthritis Research Society
International (OARSI) congress a group reported a search for eQTLs
using RNA extracted from the joint tissues of OA patients7. They
identiﬁed an eQTL in COG5 that appears to merit further study as
potentially contributing to the OA association signal.
The Tokyo GWAS
This study involved a GWAS in Japanese cases and controls,
followed by replication in Japanese and Europeans. The discovery
component of the study was small, with 899 cases and
3,396 controls, whilst the overall numbers for the discovery and
replication combined were moderate, with 1,879 cases and
4,814 controls. In the GWAS and subsequent replication in
additional Japanese cases and controls two SNPs, located within
a 340 kb region of the HLA locus on chromosome 6p, were asso-
ciated with knee OA, with P-values< 7108. However, neither
SNP showed compelling association in the European cohorts whilst
an independent replication in a Han Chinese cohort failed to
replicate the association signal8. The inability to replicate in
Europeans OA signals detected in Asians is becoming a recurring
theme and again probably reﬂects issues of clinical heterogeneity.
The arcOGEN GWAS
Panoutsopoulou and colleagues have reported on stage 1 of the
arcOGEN study, which involved a GWAS in a UK cohort followed by
replication of signals in additional European cohorts, including North
Americans of European descent5. The discovery component of the
study was reasonably powered, with 3,177 cases and 4,894 controls,whilst the overall numbers for the discovery and replication
combined were respectable, with 13,768 cases and 53,286 controls.
Although there was no signal exceeding genome-wide signiﬁcance
(P< 5108), 89 SNPs reached P-values< 104(as opposed to
51 expected under the null, P¼ 106). The strongest signal for knee
and/or hip OA was observed at rs2277831 (P¼ 2.3105), which is
located within intron 32 ofMICAL3. For knee OA the most signiﬁcant
ﬁnding was observed at rs11280 (P¼ 2.7105), within C6orf130,
whilst for hip OA the strongest signal was at rs2615977
(P¼ 1.2105), within intron 31 of COL11A1. The most salient point
from the arcOGEN report came from an analytical approach that
examined the allelic architecture of the disease, resulting in the
statement that OA is “highly polygenic with multiple variants along
the spectrum of allele frequencies contributing modest and small
effects”e in otherwords, lots of loci that’ll be hard to identify. Stage 2
of the arcOGENGWAS is due for completion soon,with the number of
cases expected to exceed 7,500. It will be of interest to know if this
larger discovery analysis identiﬁes additional novel signals.
Candidates
Despite the general gloom that surrounds the current OA GWAS
reports, with an absence of even a moderate number of compelling
signals, some light relief has emerged from some of the candidate
studies, which constitute another strategy for the mapping of
complex disease loci.
GDF5
One candidate that has stood the test of time (and several meta-
analyses) is the association to OA of the T-allele of the GDF5 50UTR
SNP rs1433839. There is now little doubt that this association is
genuine and that it shows global relevance. Furthermore, a 2011
publication reporting on functional studies of a mouse model has
further informed our understanding of the role of GDF5 in skel-
etogenesis and joint maintenance10. The brachypodism mouse is
homozygote for a frame-shift mutation of gdf5 that causes
a premature termination codon resulting in a null allele. Thesemice
have a number of abnormalities including a shortened appendic-
ular skeleton, a decrease in the length of the limb long bones, and
soft tissue deformities that clearly demonstrate the important role
of gdf5 in normal development. The 2011 study examined haplo-
insufﬁcient mice, each carrying one copy of the brachypodism
allele. Thesemice do not show developmental abnormalities but do
show an increased propensity, relative to wild type, of developing
an OA phenotype when challenged. This model, which from
amolecular genetics perspective mimics the effect of SNP rs143383
in human OA, conﬁrms the importance of maintaining adequate
levels of GDF5 protein for normal joint function and emphasizes
again the detrimental effects of quantitative alterations in gdf5/
GDF5 expression on joint tissue maintenance.
Additional publications in 2010 have revealed that rs143383 is
also associated with other musculoskeletal phenotypes, including
Achilles tendonpathology and dislocation of the hip, highlighting the
tendency of a common genotype to inﬂuence multiple phenotypes
(pleiotropy) and of the potential role that developmental factors can
have on conditions that manifest in the mature individual11,12.
At the 2010 OARSI congress we heard that GDF5 is under epige-
netic regulation in cell-lines and in patient tissues and that this
regulation may be inﬂuenced by rs143383 and a second 50UTR SNP,
rs143384,with both of these SNPs forming CpG siteswhenpresent in
their C-allele forms13. Through a deep sequencing analysis of over
1900 OA cases and controls it was also reported that in Europeans
GDF5 lacks rare variants14. Instead, the gene harbors either very
common (MAFs> 2.5%) or very rare variants (MAFs< 0.1%), with
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poor outcomes from GWAS studies; as noted earlier, it is anticipated
(hoped?) that some if not most of the missing heritability will reside
in rare variants and it is not unreasonable to expect that loci that
harbor common associated alleles will also be repositories for rare
susceptibility alleles. In Europeans this is not the case for GDF5.
Instead, the gene appears to have gone through a bottleneck inwhich
rare variants were too infrequent and were therefore eliminated.
Under this scenario, the extremely rare variants are new mutations
that have arisen after the bottleneck; a genes history can therefore be
of great relevance to its likely role in disease risk.
Overall, the OA research community’s studies of GDF5 have
moved on from genetic analysis through to epigenetic and func-
tional investigations encompassing human tissues, in vitro experi-
ments and mouse models. GDF5 is therefore turning into the
paradigm of how to move from an OA genetic association through
to a more informed and reﬁned understanding of how a risk allele
inﬂuences the phenotype.
DIO2
The regulation of thyroid hormone is critical to a number of
biological processes and although the importance of this hormone
on normal skeletogenesis has been known for some time it was not
until recently that polymorphism in the thyroid hormone signaling
pathway was convincingly implicated in OA susceptibility.
DIO2 codes for iodothyronine-deiodinase enzyme type 2 (D2),
a selenoprotein that converts intracellular inactive thyroid hormone
to its active form. D2 is a provider of local bioactive thyroid hormone
to target tissues, such as the growth plate, and is active during
normal skeletal morphogenesis aswell as inmature, adult tissues. A
linkage study initially highlighted the region of the genome
harboring DIO2, chromosome 14q32.11, as a potential OA suscepti-
bility locus15. An association analysis performed in the same study
then revealed that a commonDIO2 haplotype, containing theminor
allele of SNP rs225014 (a non-synonymous transcript SNP) and the
common allele of SNP rs12885300 (located in the 50UTR), was
associated with OA in Asian and in European cohorts, with a meta-
analysis P-value of 2.02105. Interestingly, data presented at the
2010 congress revealed that rs225014 is in high LD with an as yet
unidentiﬁed variant that inﬂuences the expression of DIO2 in
cartilage16. This discovery was made by measuring the allelic
expression of DIO2 in the RNA extracted from the cartilage of OA
patients heterozygous for rs225014. A signiﬁcantly higher expres-
sion was observed for the OA-associated C-allele of rs225014 rela-
tive to the T-allele in the majority of the patients studied. This
intriguing observation suggests that cis-acting regulatory effects
may in fact underlie some or all of the DIO2 association to OA.
The potential role in OA of polymorphism in other genes whose
proteins regulate thyroid hormone activation has also recently been
studied, with the suggestion that DIO3 polymorphism can also
modulate OA disease risk17. Overall, regulation of the availability of
thyroidhormone looks to be a promisingnovel avenue forOA studies.
IL1RN
The interleukin cluster of genes on chromosome 2q has been
investigated as potentially harboring OA susceptibility alleles for
well over a decade, with at best conﬂicting data. A meta-analysis
published in 2010 of 1,238 OA cases and 1,269 controls of European
descent failed to ﬁnd convincing evidence of association to this
cluster18 and at the 2010 OARSI congress there were four presen-
tations focusing on IL1RN, which codes for interleukin 1 receptor
antagonist19e22. These studies investigated IL1RN haplotypes
derived from SNPs rs419598, rs315952 and rs9005. The commonTTG haplotype of these three SNPs had previously been reported to
be associated with radiographic severity of knee OA, albeit in
a small cohort of 130 patients23. The ﬁrst three of the four studies
investigated small numbers of patients and they supported the TTG
association19e21 but as the sample size increased, and following
a meta-analysis of 3,676 hip and 5,128 knee cases and over 6,500
controls, the evidence weakened in the fourth study22 such that it
appears unlikely that the IL1RN TTG haplotype does code for
a signal of OA susceptibility. This is a salient lesson in the need to
maximize sample size when discovering or replicating a genetic
association.
Conclusions
Overall, when one considers the data from the GWAS and
candidate studies, there are currently only three loci that have
alleles demonstrating truly compelling association to OA across
a broad range of ethnic groups: the 7q22 locus, GDF5 and DIO2. OA
therefore currently suffers both from the missing heritability issue
and from missing loci. So what’s to be done? Looking at ongoing
genetics activity in other dichotomous diseases the options are
fairly limited: more samples, more variants (with a particular focus
on rare ones), more money, more sweat, more tears and, hopefully,
more signals. It’s also likely that sub-group analysis, focusing on
distinct phenotypes (radiographic-only, end-stage only, atrophic,
hypertrophic, pain and OA, joint shape, hand involvement, no hand
involvement, co-morbidities, etc), will follow and such plans are
once again being drawn-up24. Fortunately, such sub-group analyses
don’t require much additional funding.
So, returning to that hostage of fortunate statement. With the
power of hindsight it may come across as naïve, hubristic and
perhaps even stupid. I think however that it was just the optimism
of the time, perhaps never to be repeated again..
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